Clinical Trial Update: Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

View source ↗

Summary

Completed post-marketing surveillance study of Nexavar (sorafenib) for hepatocellular carcinoma in Japan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Status: COMPLETED